Alan M. Solinger

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2018 · 374 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

Claudia Cavelti‐Weder, Andrea Babians-Brunner, Cornelia Keller et al. · Diabetes Care · 2012 · 308 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter et al. · Journal of Allergy and Clinical Immunology · 2015 · 250 citations

Medicine, Immunology, Pharmacology +15

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study

Ahmet Gül, İlknur Tuğal-Tutkun, Charles A. Dinarello et al. · Annals of the Rheumatic Diseases · 2011 · 233 citations

Medicine, Immunology, Ophthalmology +17

Interleukin‐1 blockade by anakinra improves clinical symptoms in patients with neonatal‐onset multisystem inflammatory disease

Daniel J. Lovell, Suzanne L. Bowyer, Alan M. Solinger · Arthritis & Rheumatism · 2005 · 153 citations

Life Sciences, Immunology, Pharmacology +16